Ensysce Biosciences Inc. (ENSC)
5.28
-0.11 (-2.04%)
At close: Mar 03, 2025, 12:21 PM
Ensysce Biosciences Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Net Income | -10.63M | -24.21M | -29.15M | -160.88K | 365.95K | -1.34M | -31.19K |
| Depreciation & Amortization | n/a | n/a | 151.00 | 201.00 | 201.00 | n/a | n/a |
| Stock-Based Compensation | 879.16K | 1.07M | 121.76K | 178.68K | 6.04M | n/a | n/a |
| Other Working Capital | 107.95K | 2.84M | 120K | -998.72K | 2.46M | 126.38K | -213.47K |
| Other Non-Cash Items | -85.79K | -233.42K | 7.49M | 997.46K | 8.17M | -317.21K | -231.1K |
| Deferred Income Tax | n/a | n/a | 14.6M | -2.45M | -1.76K | 1.76K | n/a |
| Change in Working Capital | -947.08K | 5.48M | -1.3M | 185.1K | 2.46M | 273.13K | -101.5K |
| Operating Cash Flow | -10.78M | -17.89M | -8.24M | -1.25M | 10.99M | -1.24M | -251.83K |
| Capital Expenditures | 2.00 | n/a | n/a | n/a | n/a | n/a | n/a |
| Acquisitions | n/a | 4.5K | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | n/a | n/a | n/a | n/a | -566.29K | n/a | -200M |
| Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | n/a | 4.5K | n/a | 183.4M | 11.85M | 838.59K | n/a |
| Investing Cash Flow | n/a | 4.5K | n/a | 183.4M | -566.29K | 838.59K | -200M |
| Debt Repayment | 605.43K | 6.13M | 13.91M | 1.1M | 400K | n/a | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | -11.58M | n/a | n/a |
| Dividend Paid | n/a | -913.2K | -803.14B | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | -899.55K | 3.55M | -225.68K | 20.00 | 166.27K | n/a | n/a |
| Financial Cash Flow | 8.76M | 8.77M | 20.31M | 1.1M | -11.03M | -32K | 202.34M |
| Net Cash Flow | -2.02M | -9.12M | 12.07M | -147.32K | -597.25K | -431.68K | 2.09M |
| Free Cash Flow | -10.78M | -17.89M | -8.24M | -1.25M | 10.99M | -1.24M | -251.83K |